The road from protein biomarker discovery to clinical utility is rarely straight. Researchers routinely identify candidate proteins in discovery-phase experiments, only to watch those signals fail to replicate under the rigorous quantitative conditions required for translational validation.
The advent of single-cell RNA sequencing (scRNA-seq) has fundamentally redefined transcriptomic profiling by resolving transcriptional states at single cell resolution.
Unlike bulk RNA-seq, which obscures cell-to-cell variability through population averaging, scRNA-seq captures the heterogeneity, rare populations, and transitional states that underlie developmental trajectories and pathological processes. Its adoption has been rapid across immunology, oncology, neuroscience, and developmental biology, where cellular diversity is mechanistically linked to function and disease.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.
The spatial transcriptomics field provides unrivaled insights into gene expression within intact tissue architecture which is crucial for both exploratory discovery and targeted hypothesis testing. Two paradigms stand out: the 10x Genomics Visium HD platform and Xenium Prime (e.g., Xenium Prime 5K imaging-based assay). This post dissects their core technologies, strengths, and optimal use cases for advanced genomic research.
Signios Biosciences details how advanced single-cell and spatial transcriptomics support neuroscience research into Alzheimer’s, FTD, TBI, and Friedreich’s Ataxia, aiding new therapy development.
Signios Biosciences details how advanced single-cell and spatial transcriptomics support neuroscience research into Alzheimer’s, FTD, TBI, and Friedreich’s Ataxia, aiding new therapy development.
Today, we launch Signios Bio, a rebrand of what was previously known as MedGenome US Research Services. With a focus on scientific collaboration and breakthrough discovery, Signios Bio offers an integrated end-to-end suite of multiomic technologies.
Traumatic brain injury (TBI) poses complex challenges for researchers aiming to understand cellular responses post-injury. Professor Michelle H. Theus of Virginia Tech partnered with MedGenome to shed light on the cellular dynamics underlying injury progression and recovery on a murine TBI model using single-cell and spatial transcriptomics.
